Everolimus: all 667 studies that test it

Page 7 of 7. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
• Everolimus (RAD001) in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT00636922Phase 1
• Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric CancerCompletedNCT00632268Phase 2
• A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00622258Phase 1
• Everolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00618345Phase 2
• Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow upCompletedNCT00596557Phase 4
• BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)CompletedNCT00586443Phase 1
• Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate CancerCompletedNCT00574769Phase 1/2
• Erlotinib and Everolimus in Treating Patients With Metastatic Breast CancerCompletedNCT00574366Phase 1
• Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerCompletedNCT00567554Phase 3
• Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and GemcitabineCompletedNCT00560963Phase 1/2
• Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid LeukemiaStatus unknownNCT00544999Phase 1
• This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.CompletedNCT00531440Phase 3
• This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of EverolimusCompletedNCT00531063Phase 3
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal CancerCompletedNCT00522665Phase 1/2
• Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric CancerCompletedNCT00519324Phase 2
• Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00516412Phase 2
• Safe Renal Function In Long Term Heart Transplanted PatientsStatus unknownNCT00505102Phase 4
• Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant RecipientsCompletedNCT00504543Phase 2
• Phase I Study of Patupilone and RAD001CompletedNCT00496600Phase 1
• A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal CancerCompletedNCT00478634Phase 1
• Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic BreastTerminatedNCT00473005Phase 1
• Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer PatientsCompletedNCT00466466Phase 1
• Efficacy of RAD001 in Breast Cancer Patients With Bone MetastasesStatus unknownNCT00466102Phase 2
• Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant PatientsCompletedNCT00464399Phase 3
• RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1/2
• Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) PatientsCompletedNCT00457119Phase 1
• Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney CancerCompletedNCT00448149Phase 1/2
• Safety Study of RAD001 to Treat Patients With Metastatic Kidney CancerCompletedNCT00446368Phase 2
• Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant PatientsCompletedNCT00443937Phase 4
• Safety of Everolimus and Pemetrexed in Lung Cancer PatientsCompletedNCT00434174Phase 1
• Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast CancerCompletedNCT00426530Phase 1
• Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent ImplantationStatus unknownNCT00426049Phase 3
• Cisplatin and Everolimus in Treating Patients With Advanced Solid TumorsCompletedNCT00423865Phase 1
• A Study of RAD001 and Sunitinib in Metastatic Renal Cell CarcinomaCompletedNCT00422344Phase 1
• Shift to Everolimus (RAD) Kidney Sparing StudyTerminatedNCT00420537Phase 4
• A Study of Everolimus in Combination With Imatinib in Metastatic MelanomaTerminatedNCT00402662Phase 2
• Immunosuppressive Therapy With Certican (Everolimus) After Lung TransplantationCompletedNCT00402532Phase 3
• Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT00390195Phase 1/2
• Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma MultiformeCompletedNCT00387400Phase 1
• Sorafenib and RAD001 Renal Cell CarcinomaCompletedNCT00384969Phase 1
• Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host DiseaseTerminatedNCT00373815Phase 1
• S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00352443Phase 1
• Phase II Trial of RAD001 in Refractory Colorectal CancerCompletedNCT00337545Phase 2
• Pharmacokinetic Study on the Combination of Everolimus-TacrolimusStatus unknownNCT00325325Phase 2
• Vatalanib and Everolimus in Treating Patients With Advanced Solid TumorsCompletedNCT00303732Phase 1
• Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet TransplantationCompletedNCT00286624Phase 1/2
• Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid TumorsCompletedNCT00276575Phase 1
• Everolimus in Treating Patients WIth Recurrent or Metastatic Breast CancerCompletedNCT00255788Phase 2
• RAD001 Plus Docetaxel in Patients With Metastatic Breast CancerTerminatedNCT00253318Phase 1
• Everolimus for Treating Pediatric Patients With Recurrent or Refractory TumorsCompletedNCT00187174Phase 1
• Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsCompletedNCT00170885Phase 4
• Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant RecipientsCompletedNCT00170859Phase 4
• Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant PatientsCompletedNCT00170833Phase 3
• Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free RegimenCompletedNCT00170820Phase 4
• Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.CompletedNCT00170794Phase 3
• Efficacy and Safety of Everolimus in de Novo Heart Transplant RecipientsCompletedNCT00150046Phase 3
• Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT00124280Phase 2
• Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and EverolimusTerminatedNCT00117702Phase 2/3
• AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma MultiformeCompletedNCT00107237Phase 1/2
• Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal WomenCompletedNCT00107016Phase 2
• Everolimus in Treating Patients With Stage IV MelanomaCompletedNCT00098553Phase 2
• Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant PatientsCompletedNCT00098241Phase 3
• A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) PatientsCompletedNCT00098007Phase 3
• Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft VasculopathyCompletedNCT00097968Phase 3
• Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
• RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell LymphomaCompletedNCT00081874Phase 1/2

← Everolimus overview